26doc132
10.3205/26doc132
urn:nbn:de:0183-26doc1320
Meeting Abstract
SPECTRUM: Week 24 data for aflibercept 8 mg indicate improvements in patients with treatment-naïve nAMD and stable outcomes in patients with previously treated nAMD
Stahl
Stahl
Andreas
A
University Medicine Greifswald, Department of Ophthalmology, Greifswald
author
Lange
Lange
Clemens
C
Albert-Ludwig University Freiburg, Eye Center, Faculty of Medicine, Freiburg
author
Bailey
Bailey
Clare
C
University Hospitals Bristol and Weston NHS Foundation Trust, Department of Ophthalmology, Bristol, Vereinigtes Königreich
author
Konidaris
Konidaris
Vasileios
V
University Hospitals of Leicester NHS Trust, Department of Ophthalmology, Leicester, Vereinigtes Königreich
author
Chaudhary
Chaudhary
Varun
V
McMaster University, Department of Surgery, Hamilton, ON, Kanada
author
Lanzetta
Lanzetta
Paolo
P
University of Udine, Department of Medicine–Ophthalmology, Udine, Italien
author
Oubraham
Oubraham
Hassiba
H
Centre OPHTA-45, Montargis, Frankreich
author
Kirchner
Kirchner
Martin
M
Bayer AG, Leverkusen
author
Machewitz
Machewitz
Tobias
T
Bayer AG, Berlin
author
Schlief
Schlief
Sarah
S
Bayer AG, Berlin
author
Oesch
Oesch
Susanne
S
Bayer Consumer Care AG, Basel, Schweiz
author
Morgan-Warren
Morgan-Warren
Peter
P
Bayer Consumer Care AG, Basel, Schweiz
author
Munk
Munk
Marion
M
Augenarzt Praxisgemeinschaft Gutblick AG, Pfäffikon, Schweiz
author
Ambresin
Ambresin
Aude
A
Swiss Visio Montchoisi, Lausanne, Schweiz
author
German Medical Science GMS Publishing House
Düsseldorf
610
20260617
engl
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung).
M0651
132
38. Internationaler Kongress der Deutschen Ophthalmochirurgie (DOC)
Retina
Nürnberg
20260618
20260620
EPO 6.1
TextPurpose: To present Week (W) 24 results from the SPECTRUM study on the real-world effectiveness and safety of aflibercept 8 mg in patients with treatment-naïve (TN) and previously treated (PT) neovascular age-related macular degeneration (nAMD). Methods: SPECTRUM (NCT06075147) is an ongoing, global, 24-month, prospective observational study. Patients (TN or PT) with nAMD aged ≥50 years, who were prescribed aflibercept 8 mg prior to study start, were eligible. All treatment decisions are per physician discretion and local practice. The W24 analysis (visit closest to 180 [150–210] days after baseline [BL]) included the first ~150 patients enrolled globally in each nAMD cohort. Analyses were exploratory; missing values were imputed with the last observation carried forward approach. The latest data-cuts were used (April 9, 2025 and January 05, 2026 for the TN and PT nAMD cohorts). Results: The TN nAMD (n=141) and PT (n=148) nAMD cohorts had a mean age of 80.8 and 79.5 years. In the PT nAMD cohort, 71.0% of patients had previously received aflibercept 2 mg; the median time from nAMD diagnosis was 33.8 months. At W24 in the TN and PT nAMD cohorts, the mean (95% CI) change in visual acuity (VA) from BL was +3.5 (1.1, 5.8) and -0.9 (-2.6, 0.8) letters (BL: 61.6 and 63.1 letters), with a mean change in central retinal thickness (CRT) of -119 (-146, -92) and -35 (-54, -16) µm (BL: 365 and 324 µm). Patients in the TN and PT nAMD cohorts received a mean±SD of 4.7±1.2 and 4.5±1.6 injections up to Day 210 from BL. No new safety concerns were identified. Conclusions: W24 results from the SPECTRUM study of aflibercept 8 mg confirm improvements in VA and CRT in the TN nAMD cohort and stable VA and improved CRT in the PT nAMD cohort; no new safety concerns were identified.
0
0
0
0